HomeCompareOXACW vs ABBV

OXACW vs ABBV: Dividend Comparison 2026

OXACW yields 3846.15% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OXACW wins by $4916864244442.32M in total portfolio value
10 years
OXACW
OXACW
● Live price
3846.15%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4916864244442.43M
Annual income
$4,677,622,848,903,583,000.00
Full OXACW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OXACW vs ABBV

📍 OXACW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOXACWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OXACW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OXACW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OXACW
Annual income on $10K today (after 15% tax)
$326,923.08/yr
After 10yr DRIP, annual income (after tax)
$3,975,979,421,568,045,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OXACW beats the other by $3,975,979,421,568,024,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OXACW + ABBV for your $10,000?

OXACW: 50%ABBV: 50%
100% ABBV50/50100% OXACW
Portfolio after 10yr
$2458432122221.26M
Annual income
$2,338,811,424,451,803,600.00/yr
Blended yield
95.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OXACW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OXACW buys
0
ABBV buys
0
No recent congressional trades found for OXACW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOXACWABBV
Forward yield3846.15%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4916864244442.43M$102.3K
Annual income after 10y$4,677,622,848,903,583,000.00$24,771.77
Total dividends collected$4900517942979.50M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OXACW vs ABBV ($10,000, DRIP)

YearOXACW PortfolioOXACW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$395,315$384,615.38$11,550$430.00+$383.8KOXACW
2$14,632,742$14,209,755.02$13,472$627.96+$14.62MOXACW
3$507,226,418$491,569,383.96$15,906$926.08+$507.21MOXACW
4$16,467,649,516$15,924,917,248.20$19,071$1,382.55+$16467.63MOXACW
5$500,816,191,496$483,195,806,513.88$23,302$2,095.81+$500816.17MOXACW
6$14,269,528,055,601$13,733,654,730,700.87$29,150$3,237.93+$14269528.03MOXACW
7$380,975,666,457,248$365,707,271,437,754.06$37,536$5,121.41+$380975666.42MOXACW
8$9,532,740,038,130,830$9,125,096,075,021,576.00$50,079$8,338.38+$9532740038.08MOXACW
9$223,590,089,288,638,900$213,390,057,447,838,900.00$69,753$14,065.80+$223590089288.57MOXACW
10$4,916,864,244,442,426,000$4,677,622,848,903,583,000.00$102,337$24,771.77+$4916864244442.32MOXACW

OXACW vs ABBV: Complete Analysis 2026

OXACWStock

Oxbridge Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify a target in the disruptive technology market. The company was incorporated in 2021 and is based in Georgetown, Cayman Islands.

Full OXACW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OXACW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OXACW vs SCHDOXACW vs JEPIOXACW vs OOXACW vs KOOXACW vs MAINOXACW vs JNJOXACW vs MRKOXACW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.